Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Fungal Endophthalmitis

  • Author: Lihteh Wu, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: Mar 11, 2016
 

Background

Fungi are eukaryotic organisms that are ubiquitous in nature. The following 3 classes of fungi are important ocular pathogens: molds, yeasts, and diphasic fungi. Molds, also known as filamentous fungi, are multicellular organisms that form a tangled mass known as the mycelium. From this mass, filamentous projections, known as hyphae, branch out. The hyphae may be septate or nonseptate. Septate hyphae have true divisions, subdividing them into several cells, while nonseptate hyphae have no true divisions. Common septate filamentous fungi are Aspergillus, Fusarium, Cephalosporium, Paecilomyces, and Penicillium species. The nonseptate filamentous fungi include the Mucor species.

Yeasts are unicellular organisms that may develop pseudohyphae. Candida and Cryptococcus are the important ocular pathogens. The diphasic fungi exist in 2 forms, yeast and mold. Important ocular pathogens include Histoplasma, Blastomyces, and Coccidioides.

Endophthalmitis refers to intraocular inflammation involving the vitreous and anterior chamber of the eye. In most cases, endophthalmitis results from an infectious organism. Fungal endophthalmitis can be divided into the less common endogenous infections and the more common exogenous infections.

Endogenous fungal endophthalmitis represents intraocular dissemination of a systemic fungal infection. Among the different fungal species, Candida species is the most common cause of infection, followed by Aspergillus species.[1] Risk factors include immunosuppression, intravenous drug abuse, bacterial sepsis, prolonged hyperalimentation, systemic antibiotics, corticosteroid therapy, recent abdominal surgery, malignancy, alcoholism, diabetes mellitus, trauma, and hemodialysis.[2, 3, 4]

Exogenous infections usually are secondary to trauma or surgery. A variety of fungi, including Paecilomyces, Acremonium, and Sporothrix species, has been associated with endophthalmitis following intraocular surgery or trauma. Fungal endophthalmitis is a rare complication after cataract surgery. The most common causative fungal pathogens implicated in fungal endophthalmitis after cataract surgery include Candida species and molds such as Aspergillus and Fusarium species.[5] There have been recent outbreaks of fungal endophthalmitis associated with contaminated compounded brilliant blue G and triamcinolone.[6]

Next

Pathophysiology

Candidal endophthalmitis

Even though Candida albicans is by far the most common cause of endogenous endophthalmitis,[7] other non– C albicans species, in particular C tropicalis, have also been implicated in intraocular infections[8] . The most common risk factors are those that predispose to candidemia (eg, a prior history of gastrointestinal surgery, hyperalimentation, and diabetes mellitus).[9]

Surprisingly, immunosuppression alone does not significantly increase the risk of Candida entering the bloodstream (eg, candidal chorioretinitis is an uncommon ophthalmic condition in AIDS patients). Furthermore, Candida endophthalmitis can occur after abdominal surgery or in diabetic patients without granulocytopenia. Rao and Hidayat have suggested that Candida overgrowth in the gastrointestinal tract and the increased availability of glucose seen in diabetic patients promote the growth of Candida.[9] The intravitreal concentration of glucose is higher in diabetic patients when compared with nondiabetic patients, which may explain Candida' s predilection for the vitreous.[10]

C albicans is by far the most common cause of endogenous endophthalmitis. They are commensal organisms that reside in the human body and are found normally in the female genital tract, the gastrointestinal tract, and the respiratory tract.

These fungi are kept in check by the host's normal immune response. When a breakdown in the host's immune system occurs, fungi may spread throughout the body. Many organs, including the eye, can be affected by this spread of fungi through the bloodstream. However, immunosuppression alone does not increase significantly the risk of fungi entering the bloodstream. For instance, candidal chorioretinitis is an uncommon ophthalmic condition in AIDS patients. Neutrophils are apparently important in the first-line defense against candidal organisms. Infection probably starts in the choroid and spreads to the retina and vitreous.

Patients who are at risk include patients with longstanding indwelling catheters; persons who use intravenous drugs; postpartum women; premature infants; patients undergoing hyperalimentation; patients with a history of recent abdominal surgery; and patients with debilitating diseases, such as diabetes mellitus, postorgan transplantation, or malignancies.

Aspergillus endophthalmitis

Of the more than 200 species of Aspergillus, A flavus and A fumigatus are the most common pathogenic organisms in humans. They are ubiquitous organisms found in soil, decaying matter, water, and organic debris. Its conidia, the asexual spores of aspergilli organisms are airborne, so inhalation is an important route of entry into the human body. When conidia enter the terminal alveoli of the lung, they may be engulfed by mononuclear phagocytes. If conidia are not destroyed by this first line of defense, they germinate and extend mycelial structures that are associated with tissue invasion. Neutrophils constitute the second line of defense and kill the mycelia.

In patients who are at risk, such as those patients with chronic pulmonary diseases or those patients with orthotopic liver transplants, renal transplants, leukemia and other hematologic disorders, Goodpasture syndrome, alcoholism, prematurity, and bone marrow transplants, disseminated aspergillosis may result. The most common predisposing factors include intravenous drug abuse, prior cardiac surgery, and organ transplant recipient. The common denominator in these patients appears to be granulocytopenia.[9] The fungus usually gains access to the eye as it spreads from the lungs to the choroid.

Cryptococcal endophthalmitis

Pigeons play an important role in the pathogenesis of cryptococcosis. Cryptococci spores can survive up to 2 years in pigeon droppings. Spores gain access to the human body through inhalation. From the lungs, the fungus is disseminated hematogenously and preferentially affects the central nervous system. It is the most common cause of fungal meningitis. Cryptococci organisms reach the eye through either direct extension from the optic nerve sheath or hematogenously from a distant focus. The choroid is probably the first site of ocular infection.

Coccidioides endophthalmitis

Coccidioides endophthalmitis results from the inhalation of Coccidioides immitis arthroconidia, which are found in the dust of endemic areas. Agricultural workers and constructions crews are at risk. In most patients, the inhalation of the spores leads to a self-limited respiratory disease. In few patients who are reexposed to the fungus, a chronic respiratory disease ensues. Hematogenous dissemination to the eye can occur.

Previous
Next

Epidemiology

Frequency

United States

Compared to previous decades, the incidence of endogenous endophthalmitis appears to have increased in the past few decades. This may be secondary to an increase in intravenous drug use; the advent of chemotherapy for cancer patients; and the increased ability to care for more debilitated patients with hyperalimentation, indwelling catheters, and potent antibiotics.

Prospective studies of hospitalized patients with candidemia reveal that 9-37% of patients developed candidal endophthalmitis. In studies where prompt treatment of a systemic fungal infection is instituted, only 3-9% patients developed endogenous fungal endophthalmitis. A prospective cohort study that enrolled 125 inpatients with positive fungal blood culture results showed a 5.6% rate of chorioretinitis and 1.6% rate of endophthalmitis.[11] Despite modern antifungal therapy, fungal chorioretinitis and endophthalmitis continue to occur in patients with positive fungal culture results.

International

In countries with temperate climates, endophthalmitis usually results from an infectious organism such as bacteria. Fungal endophthalmitis remains a relatively rare condition.[12] However, in countries with tropical climates, fungal endophthalmitis is not an infrequent finding. In India, fungi were isolated in 22% of culture-proven endophthalmitis.[13]

Because it is commensal in the human body, Candida species are found throughout the world. Cryptococci and aspergilli also are present worldwide and found in both urban settings and rural settings.

C immitis is endemic in the southwestern United States (the San Joaquin Valley) and Northern Mexico. It also has been reported in Honduras, Venezuela, and Colombia.

Race

No racial predisposition has been observed.

Sex

A male preponderance is reported for endogenous fungal endophthalmitis.

Age

With regard to endogenous fungal endophthalmitis, there are 2 incidence peaks: one in patients younger than 1 year, and the other in middle-aged patients.

Previous
Next

Prognosis

The prognosis of fungal endophthalmitis depends on the virulence of the organism, the extent of intraocular involvement, and the timing and mode of interventions.

Infections secondary to molds have a worse outcome than those due to yeasts.[3]

Prompt therapy following early diagnosis helps to reduce significant visual loss in all forms of fungal endophthalmitis.

The visual outcome of Aspergillus endophthalmitis usually is poor because of the preferred macular involvement by the fungus.

Previous
 
 
Contributor Information and Disclosures
Author

Lihteh Wu, MD Asociados de Macula Vitreo y Retina de Costa Rica

Lihteh Wu, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Association for Research in Vision and Ophthalmology, Club Jules Gonin, Macula Society, Pan-American Association of Ophthalmology, Retina Society

Disclosure: Received income in an amount equal to or greater than $250 from: Bayer Health; Quantel Medical; Heidelberg Engineering.

Coauthor(s)

Dhariana Acón, MD Ophthalmologist, Caja Costarricense Seguro Social, Hospital de Guapiles, Costa Rica

Disclosure: Nothing to disclose.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

R Christopher Walton, MD Professor, Director of Uveitis and Ocular Inflammatory Disease Service, Department of Ophthalmology, University of Tennessee College of Medicine

R Christopher Walton, MD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Retina Society, American College of Healthcare Executives, American Uveitis Society

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Andrew A Dahl, MD, FACS Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Andrew A Dahl, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, American Intraocular Lens Society, American Medical Association, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Medical Society of the State of New York, New York State Ophthalmological Society, Outpatient Ophthalmic Surgery Society

Disclosure: Nothing to disclose.

Acknowledgements

Teodoro Evans, MD Consulting Surgeon, Vitreo-Retinal Section, Clinica de Ojos, Costa Rica

Disclosure: Nothing to disclose.

Rafael Alberto García, MD Chief of Outpatient Services, Department of Ophthalmology, Hospital México of San José, Costa Rica

Disclosure: Nothing to disclose.

References
  1. Essman TF, Flynn HW Jr, Smiddy WE, Brod RD, Murray TG, Davis JL. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers. 1997 Mar. 28(3):185-94. [Medline].

  2. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000 Oct. 13(4):662-85. [Medline].

  3. Sridhar J, Flynn HW Jr, Kuriyan AE, Miller D, Albini T. Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections. J Ophthalmic Inflamm Infect. 2013. 3(1):60. [Medline].

  4. Sridhar J, Flynn HW Jr, Kuriyan AE, Miller D, Albini T. Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections. J Ophthalmic Inflamm Infect. 2013 Sep 20. 3 (1):60. [Medline].

  5. Smith TC, Benefield RJ, Kim JH. Risk of Fungal Endophthalmitis Associated with Cataract Surgery: A Mini-Review. Mycopathologia. 2015 Dec. 180 (5-6):291-7. [Medline].

  6. Mikosz CA, Smith RM, Kim M, Tyson C, Lee EH, Adams E. Fungal endophthalmitis associated with compounded products. Emerg Infect Dis. 2014 Feb. 20(2):248-56. [Medline].

  7. Schiedler V, Scott IU, Flynn HW, Davis JL, Benz MS, Miller D. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol. 2004 Apr. 137(4):725-31. [Medline].

  8. Shah CP, McKey J, Spirn MJ, Maguire J. Ocular candidiasis: a review. Br J Ophthalmol. 2008 Apr. 92(4):466-8. [Medline].

  9. Rao NA, Hidayat A. A comparative clinicopathologic study of endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared to aspergillosis. Trans Am Ophthalmol Soc. 2000. 98:183-93; discussion 193-4. [Medline].

  10. Lundquist O, Osterlin S. Glucose concentration in the vitreous of nondiabetic and diabetic human eyes. Graefes Arch Clin Exp Ophthalmol. 1994 Feb. 232(2):71-4. [Medline].

  11. Paulus YM, Cheng S, Karth PA, Leng T. PROSPECTIVE TRIAL OF ENDOGENOUS FUNGAL ENDOPHTHALMITIS AND CHORIORETINITIS RATES, CLINICAL COURSE, AND OUTCOMES IN PATIENTS WITH FUNGEMIA. Retina. 2015 Dec 11. [Medline].

  12. Lalwani GA, Flynn HW Jr, Scott IU, Quinn CM, Berrocal AM, Davis JL, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology. 2008 Mar. 115(3):473-6. [Medline].

  13. Anand A, Madhavan H, Neelam V, Lily T. Use of polymerase chain reaction in the diagnosis of fungal endophthalmitis. Ophthalmology. 2001 Feb. 108(2):326-30. [Medline].

  14. Sakai T, Kohzaki K, Watanabe A, Tsuneoka H, Shimadzu M. Use of DNA microarray analysis in diagnosis of bacterial and fungal endophthalmitis. Clin Ophthalmol. 2012. 6:321-6. [Medline].

  15. William A, Spitzer MS, Deuter C, Blumenstock G, Partsch M, Voykov B, et al. Outcomes of Primary Transconjunctival 23-Gauge Vitrectomy in the Diagnosis and Treatment of Presumed Endogenous Fungal Endophthalmitis. Ocul Immunol Inflamm. 2016 Jan 30. 1-7. [Medline].

  16. Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy. 2007 Dec. 27(12):1711-21. [Medline].

  17. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002 Dec 19. 347(25):2020-9. [Medline].

  18. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis. 2005 Aug 1. 41(3):e27-8. [Medline].

  19. Mikosz CA, Smith RM, Kim M, Tyson C, Lee EH, Adams E, et al. Fungal endophthalmitis associated with compounded products. Emerg Infect Dis. 2014 Feb. 20 (2):248-56. [Medline].

  20. Sallam A, Taylor SR, Khan A, McCluskey P, Lynn WA, Manku K. FACTORS DETERMINING VISUAL OUTCOME IN ENDOGENOUS CANDIDA ENDOPHTHALMITIS. Retina. 2012 Jan 31. [Medline].

  21. Tanaka H, Ishida K, Yamada W, Nishida T, Mochizuki K, Kawakami H. Study of ocular candidiasis during nine-year period. J Infect Chemother. 2016 Mar. 22 (3):149-56. [Medline].

  22. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis. 1995 Mar. 20(3):657-64. [Medline].

  23. Blumenkranz MS, Stevens DA. Therapy of endogenous fungal endophthalmitis: miconazole or amphotericin B for coccidioidal and candidal infection. Arch Ophthalmol. 1980 Jul. 98(7):1216-20. [Medline].

  24. Breit SM, Hariprasad SM, Mieler WF et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol. 2005 Jan. 139(1):135-40. [Medline].

  25. Brod RD, Flynn HW, Clarkson JG, Pflugfelder SC, Culbertson WW, Miller D. Endogenous Candida endophthalmitis. Management without intravenous amphotericin B. Ophthalmology. 1990 May. 97(5):666-72; disc: 672-4. [Medline].

  26. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med. 1989 Oct. 149(10):2226-8. [Medline].

  27. Christmas NJ, Smiddy WE. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers. 1996 Dec. 27(12):1012-8. [Medline].

  28. Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002. 45 Suppl 3:56-60. [Medline].

  29. Crump JR, Elner SG, Elner VM, Kauffman CA. Cryptococcal endophthalmitis: case report and review. Clin Infect Dis. 1992 May. 14(5):1069-73. [Medline].

  30. Donahue SP, Greven CM, Zuravleff JJ, Eller AW, Nguyen MH, Peacock JE Jr, et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology. 1994 Jul. 101(7):1302-9. [Medline].

  31. Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore). 1974 Jan. 53(1):47-75. [Medline].

  32. Gao H, Pennesi ME, Shah K, Qiao X, Hariprasad SM, Mieler WF, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol. 2004 Nov. 122(11):1687-92. [Medline].

  33. Griffin JR, Pettit TH, Fishman LS, Foos RY. Blood-borne Candida endophthalmitis. A clinical and pathologic study of 21 cases. Arch Ophthalmol. 1973 Jun. 89(6):450-6. [Medline].

  34. Gross JG. Endogenous Aspergillus-induced endophthalmitis. Successful treatment without systemic antifungal medication. Retina. 1992. 12(4):341-5. [Medline].

  35. Henderson DK, Edwards JE Jr, Montgomerie JZ. Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J Infect Dis. 1981 May. 143(5):655-61. [Medline].

  36. Hunt KE, Glasgow BJ. Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Ophthalmology. 1996 May. 103(5):757-67. [Medline].

  37. Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster HA. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol. 1995 Apr. 119(4):477-81. [Medline].

  38. Martinez-Vazquez C, Fernandez-Ulloa J, Bordón J, Sopena B, de la Fuente J, Ocampo A, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis. 1998 Nov. 27(5):1130-3. [Medline].

  39. McDonald HR, De Bustros S, Sipperley JO. Vitrectomy for epiretinal membrane with Candida chorioretinitis. Ophthalmology. 1990 Apr. 97(4):466-9. [Medline].

  40. Naoi N, Sawada A. Effect of vitrectomy on epiretinal membranes after endogenous fungal endophthalmitis. Jpn J Ophthalmol. 1996. 40(3):434-8. [Medline].

  41. Okhravi N, Adamson P, Mant R, Matheson MM, Midgley G, Towler HM, et al. Polymerase chain reaction and restriction fragment length polymorphism mediated detection and speciation of Candida spp causing intraocular infection. Invest Ophthalmol Vis Sci. 1998 May. 39(6):859-66. [Medline].

  42. Okhravi N, Dart JK, Towler HM, Lightman S. Paecilomyces lilacinus endophthalmitis with secondary keratitis: a case report and literature review. Arch Ophthalmol. 1997 Oct. 115(10):1320-4. [Medline].

  43. Ozdamar A, Aras C, Ozturk R, Akin E, Karacorlu M, Ercikan C. In vitro antimicrobial activity of silicone oil against endophthalmitis-causing agents. Retina. 1999. 19(2):122-6. [Medline].

  44. Parke DW 2nd, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology. 1982 Jul. 89(7):789-96. [Medline].

  45. Scherer WJ, Lee K. Implications of early systemic therapy on the incidence of endogenous fungal endophthalmitis. Ophthalmology. 1997 Oct. 104(10):1593-8. [Medline].

  46. Sheu SJ, Chen YC, Kuo NW, et al. Endogenous cryptococcal endophthalmitis. Ophthalmology. 1998 Feb. 105(2):377-81. [Medline].

  47. Smiddy WE. Treatment outcomes of endogenous fungal endophthalmitis. Curr Opin Ophthalmol. 1998 Jun. 9(3):66-70. [Medline].

  48. Smith SR, Kroll AJ, Lou PL, Ryan EA. Endogenous bacterial and fungal endophthalmitis. Int Ophthalmol Clin. 2007. 47(2):173-83. [Medline].

  49. Weishaar PD, Flynn HW, Murray TG, Davis JL, Barr CC, Gross JG, et al. Endogenous Aspergillus endophthalmitis: clinical features and treatment outcomes. Ophthalmology. 1998 Jan. 105(1):57-65. [Medline].

  50. Weissgold DJ, Maguire AM, Brucker AJ. Management of postoperative acremonium endophthalmitis. Ophthalmology. 1996 May. 103(5):749-56. [Medline].

  51. Zakka KA, Foos RY, Brown WJ. Intraocular coccidioidomycosis. Surv Ophthalmol. 1978 Mar-Apr. 22(5):313-21. [Medline].

  52. Zhang YQ, Wang WJ. Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina. 2005 Sep. 25(6):746-50. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.